Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical...
Asian Growth Leaders With High Insider Ownership June 2026
The highest expected increase exceeds 32 times, nearly 90% of companies forecast positive results, and the A-share first quarter report has "opened with a bang."
Innovative drug concept stocks continue to be strong, with Menovo hitting a 3-day consecutive limit up, followed by Fushine, BHC, Kingchem, APELOA, and WuXi AppTec
CRO concept stocks fluctuated and strengthened, with Fushine and Menovo both hitting the daily limit, Kingchem rising more than 10%, and Biocytogen, BHC, and ChemPartner following suit
A-share innovative drug concept stocks are active again, Sunshine Guojian Pharmaceutical rose over 10% to a new high, Yatai Pharm had two consecutive limit-ups, WECOME rose over 10%, and Baicheng Pharmaceutical, ALK, and Fushine followed suit
Fushine: Net profit loss of 55.8404 million yuan in the third quarter, a decrease of 40.96%